OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
January 04, 2021
Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.
November 24, 2020
Wacker will support production of CureVac’s COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.
November 03, 2020
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.
October 20, 2020
The company’s new closed cell therapy processing system enables scalable, cost-effective development and manufacturing of cell therapies.
October 03, 2020
The manufacture of gene therapy vectors is shifting to more modern technologies.
Industry experts discuss challenges and best practices for scaling up manufacturing under a short deadline.
February 06, 2020
Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.
December 02, 2019
As equipment evolves and use of PAT increases, DOE is becoming an integral part of upstream bioprocess development.
September 11, 2019
The company’s Custom Single Run product line now has available bioreactors with working volumes of up to 6000 L.
September 03, 2019
The new facility, located in Ness Ziona, Israel, will support clinical phage manufacturing and can be expanded in the future to support commercial-scale manufacturing.